Post by Harbour BioMed

Just weeks after the FDA clearance, we are pleased to share that the National Medical Products Administration (NMPA) of China has accepted the IND application for HBM7004, our novel B7H4xCD3 bispecific antibody for advanced solid tumors. 👏 👏 Developed on our proprietary HBICE® platform, HBM7004 is designed to offer a differentiated approach in cancer immunotherapy—aiming to unlock both enhanced efficacy and improved safety. What makes this exciting? ✅ Tumor-dependent activation – Intratumor B7H4-dependent T cell activation ✅ Strong efficacy + stability – Demonstrated anti-tumor activity in multiple animal models with remarkable in vivo stability and reduced systemic toxicity ✅ Synergy potential – Combinability with B7H4x4-1BB bispecific antibody at a low effector-to-target cell ratio We look forward to advancing HBM7004 toward clinical evaluation in China and beyond. 👉 Read the full press release: https://lnkd.in/gFzUs4sC #ImmunoOncology #BispecificAntibodies #IND #NMPA #CancerResearch #HBICE